Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with müllerian carcinoma (Epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: A phase II study of the Japanese gynecologic oncology group

Japanese Journal of Clinical Oncology

Volumn 38, Issue 11, 2008, Pages 777-785

  Katsumata, Noriyuki ^a   Fujiwara, Yasuhiro ^a   Kamura, Toshiharu ^b   Nakanishi, Toru ^c   Hatae, Masayuki ^d   Aoki, Daisuke ^e   Tanaka, Kenichi ^f   Tsuda, Hiroshi ^g   Kamiura, Shoji ^h   Takehara, Kazuhiro ⁱ   Sugiyama, Toru ^j   Kigawa, Junzo ^k   Fujiwara, Keiichi ^l   Ochiai, Kazunori ^m   Ishida, Ryo ⁿ   Inagaki, Mitsuo ⁿ   Noda, Kiichiro ^o  

^a NATIONAL CANCER CENTER   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d Kagoshima City Hospital   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER   (Japan)

^j IWATE MEDICAL UNIVERSITY   (Japan)

^k TOTTORI UNIVERSITY   (Japan)

^l KAWASAKI MEDICAL SCHOOL   (Japan)

^m JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ Janssen Pharmaceutical KK   (Japan)

^o KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chemo gynaecology; Chemo phase I II III; Hand foot syndrome; M llerian carcinoma; Ovarian carcinoma; Pegylated liposomal doxorubicin; Ynaecology

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHEST TIGHTNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROPENIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HISTOPATHOLOGY; HOT FLUSH; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE REACTION; JAPANESE; LEUKOPENIA; LOW BACK PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SODIUM BLOOD LEVEL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DOXORUBICIN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; JAPAN; LIPOSOMES; MIDDLE AGED; MIXED TUMOR, MULLERIAN; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 55149099861     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn101     Document Type: Article

References (25)

1. Udagawa Y, Yaegashi Y. Ovarian Cancer Treatment Guideline. Japan Society of Gynecologic Oncology. 2nd edn. Tokyo: Kanehara & Co., Ltd 2007.
2. Markman M, Zaino RJ, Fleming PA, Gemignani ML. Carcinoma of the Fallopian Tube. In: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M editors. Principles and Practice of Gynecologic Oncology 4th edn. Philadelphia: Lippincott Williams & Wilkins 2004;1035-53.
3. Karlan BY, Markman MA, Eifel PJ. Ovarian Cancer, Peritoneal Carcinoma, and Fallopian Tube Carcinoma. In: Devita VT Jr, Hellman S, Rosenberg SA editors. Cancer Principles & Practice of Oncology. 7th edn. Philadelphia: Lippincott Williams & Wilkins 2005;1364-97.
4. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36.
5. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
6. Woodle MC. Surface-modified liposomes: Assessment and characterization for increased stability and prolonged blood circulation. Chem Phys Lipids 1993;64:249-62.
7. Needham D, McIntosh TJ, Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1992;1108:40-8.
8. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993;143:10-4.
9. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992;52:5135-43.
10. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
11. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18:3093-100.
12. Johnston SRD, Gore ME. Caelyx: Phase II studies ovarian cancer. Eur J Cancer 2001;37(Suppl. 9):S8-14.
13. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
14. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated loposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
15. O'Byrne KJ, Bliss P, Graham JD, Gerber J, Vasey PA, Khanna S, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002;21:203a [Abstract 808].
16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer V.1.2008. Available from: http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf.
17. National Cancer Institute. Ovarian Epithelial Cancer Treatment (PDQ®) Health Professional Version Recurrent or Persistent Ovarian Epithelial Cancer. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/ ovarianepithelial/HealthProfessional/page7.
18. National Institute for Health and Clinical Excellence. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. Available from: http://guidance.nice.org.uk/TA91.
19. Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y'Tamura T. Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors. Jpn J Clin Oncol 2006;36:768-74.
20. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 2007;25:2811-8.
21. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): Possible role in hypersensitivity reactions. Ann Oncol 2003;14:1430-7.
22. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
23. Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: A GINECO phase II trial. Ann Oncol 2007;18:263-8.
24. du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 2007;107:518-25.
25. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008;108:90-4.